MYLK-AS2

Across TCGA pan-cancer cohorts, MYLK-AS2 RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of MYLK-AS2’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where MYLK-AS2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MYLK-AS2 is over-expressed in tumor, although a few such as COAD and KICH show the opposite, repressed pattern.

LIHC, BLCA, and HNSC are the cancer types where MYLK-AS2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MYLK-AS2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	All	All	+0.040	<.001	8	view →
BLCA	All	All	+0.059	.033	4	view →
HNSC	All	All	+0.055	.012	4	view →
COAD	All	III,IV	−0.045	.005	4	view →
CHOL	Female	All	+0.276	.004	2	view →
PAAD	Male	All	+0.150	.017	2	view →
KICH	All	All	−0.081	.002	2	view →
THCA	All	All	−0.015	.019	2	view →
KIRC	Male	IV	+0.055	.011	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

MYLK-AS2–LIHC

Open the LIHC breakdown →